会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Oncolytic viruses as phenotyping agents for neoplasms
    • 肿瘤溶解病毒作为肿瘤的表型剂
    • US20040029112A1
    • 2004-02-12
    • US10602024
    • 2003-06-24
    • Oncolytics Biotech Inc.
    • Bradley G. ThompsonMatthew C. Coffey
    • C12Q001/70
    • G01N33/574G01N33/5748G01N2333/14Y10S435/975
    • The present invention provides a method of diagnosing neoplasms having a particular phenotype by using oncolytic viruses that selectively replicate in neoplasms having the particular phenotype. For example, reovirus does not replicate in normal cells. However, reovirus selectively replicate in cells with an activated ras pathway, which leads to death of these cells. Therefore, a cell which becomes neoplastic due to, at least in part, elevated ras pathway activities can be diagnosed by its susceptibility to reovirus replication. This invention can further be applied, using other oncolytic viruses, to the diagnosis and/or treatment of other tumors, such as interferon-sensitive tumors, p53-deficient tumors and Rb-deficient tumors. Kits useful in the diagnosis or treatment disclosed herein are also provided.
    • 本发明提供了通过使用在具有特定表型的肿瘤中选择性复制的溶瘤病毒来诊断具有特定表型的赘生物的方法。 例如,呼肠孤病毒不会在正常细胞中复制。 然而,呼肠孤病毒在具有活化的ras途径的细胞中选择性复制,这导致这些细胞的死亡。 因此,由于至少部分地升高的ras途径活性而变得肿瘤的细胞可以通过其对呼肠孤病毒复制的易感性来诊断。 本发明还可以使用其他溶瘤病毒来应用于其它肿瘤如干扰素敏感性肿瘤,p53缺陷型肿瘤和Rb缺陷型肿瘤的诊断和/或治疗。 还提供了在本文公开的诊断或治疗中有用的试剂盒。
    • 5. 发明申请
    • Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders
    • 用于预防呼肠孤病毒识别用于治疗细胞增殖性疾病的方法
    • US20030215443A1
    • 2003-11-20
    • US10401032
    • 2003-03-28
    • Oncolytics Biotech Inc.
    • Matthew C. CoffeyBradley G. Thompson
    • A61K039/395
    • A61K35/765A61K38/13C07K16/081C07K16/10C07K16/4216C12N9/1205C12N2720/12232Y10S435/948Y10S435/975A61K2300/00
    • The present invention pertains to methods for preventing reovirus recognition in the treatment of cellular proliferative disorders, and particularly ras-mediated cellular proliferative disorders, in mammals. The mammal may be selected from dogs, cats, sheep, goats, cattle, horses, pigs, mice, humans and non-human primates. The method comprises suppressing or otherwise inhibiting the immune system of the mammal and, concurrently or subsequently, administering to the proliferating cells an effective amount of one or more reoviruses under conditions which result in substantial lysis of the proliferating cells. In particular, the methods provide for reovirus treatment of immunosuppressed or immuno-deficient mammals to treat the proliferative disorders. Immunosuppression, immunoinhibition or otherwise inducing an immunodeficient state in a mammal renders the reovirus more effective. The methods may include the selective removal of immune constituents that may interfere with the systemic delivery of the virus; preventing reovirus recognition by the host immune system; and removal of the virus from an immune suppressed or immune incompetent host following treatment with reovirus. Alternatively, reovirus may be administered to a mammal with a diminished immune response system under conditions which result in substantial lysis of the proliferating cells. Immune systems may be compromised by one or more of the following: an HIV infection; as a side effect of chemotherapy or radiation therapy; by selective removal of B and/or T cell populations; by removal of antibodies (anti-antireovirus antibodies or all antibodies), and the like.
    • 本发明涉及在哺乳动物中治疗细胞增殖性疾病,特别是ras介导的细胞增殖性疾病中预防呼肠孤病毒识别的方法。 哺乳动物可以选自狗,猫,绵羊,山羊,牛,马,猪,小鼠,人和非人灵长类动物。 该方法包括抑制或以其他方式抑制哺乳动物的免疫系统,并且同时或随后在导致增殖细胞的实质性裂解的条件下向增殖细胞施用有效量的一种或多种呼吸道病毒。 特别地,该方法提供了呼肠孤病毒治疗免疫抑制或免疫缺陷型哺乳动物以治疗增殖性疾病。 在哺乳动物中的免疫抑制,免疫抑制或其他诱导免疫缺陷状态使呼肠孤病毒更有效。 所述方法可以包括选择性去除可能干扰病毒的全身递送的免疫组分; 预防宿主免疫系统的呼肠孤病毒识别; 并在用呼肠孤病毒治疗后从免疫抑制或免疫不称职的宿主中除去病毒。 或者,呼肠孤病毒可以在导致增殖细胞的实质性裂解的条件下给予具有减少的免疫应答系统的哺乳动物。 免疫系统可能受到以下一种或多种感染:HIV感染; 作为化疗或放射治疗的副作用; 通过选择性去除B和/或T细胞群体; 通过除去抗体(抗 - 抗病毒抗体或全部抗体)等。